Pane wikiwiki
E aʻo pehea ka hana ʻana o ka n-of-1 i ka hoʻokele ʻana i ka palapala hoʻomohala maʻi mRNA pilikino i nā papahana peptide kiʻekiʻe-a me nā huahana modular…
ʻO ke kumu hoʻohālike n-o-1 a me kāna mau ʻano like ʻole ma Peptide R&ʻO D
Nā lawelawe Pono nā lāʻau lapaʻau mRNA pilikino i hoʻokahi pahu hana i kēlā me kēia maʻi, no kēlā me kēia pōʻaiapuni lapaʻau. ʻO kēlā me kēia pūʻulu e pili ana i ka genomic sequencing, helu helu neoantigen prioritization, mRNA hana, hoʻokumu ʻana i ka lipid nanoparticle, a hoʻokuʻu i ka hoʻāʻo—nā mea a pau i loko o kahi puka lapaʻau i ana ʻia i nā pule. A 2026 ka nānā ʻana i paʻi ʻia ma BioPharma Dive ua ʻike ʻo ka hoʻolaha ʻana i ka pāʻoihana o kēia mau kano e koi ai i "mau ʻumi kaukani o nā pūʻulu pākahi,"ʻo ia ka mea i "haʻihaʻi nui i ke kumu hoʻohālike hana maʻamau."
Nā polokalamu peptide e hana ana ma waena o ka hoʻomohala ʻana i ka maʻi neoantigen, MHC-peptide tetramer panel, a i ʻole nā hale waihona puke kānana kiʻekiʻe e kū nei i kahi paʻakikī like ʻole. Pono paha kahi papahana ʻike hoʻokahi i 15-30 mau kaʻina hana maʻamau i hoʻohui ʻia ma ka milligram a i ka nui-gram scale., kēlā me kēia me kona ʻano hoʻololi ponoʻī, koi hoʻomaʻemaʻe, a hoʻokuʻu kikoʻī. ʻO ka neʻe maikaʻi ʻana ma waena o nā kaʻina - me ka ʻole o ke kūkulu hou ʻana i ka ʻōnaehana analytical a me nā palapala i kēlā me kēia manawa-he ʻāpana hiki ke kuhikuhi pololei i nā mea hana mRNA e hana nei e pani..
ʻEhā mau loina hana e hoʻoponopono i kēia āpau. Loaʻa kēlā me kēia mai ka hoʻomaʻamaʻa peptide CMC i hoʻokumu ʻia a mai nā palapala hana modular e puka mai ana no ka therapeutics pilikino..
Haʻawina 1: Hoʻemi ʻo Modular Production Architecture i ka Sequence-Change Risk
No ke aha ia mea. ʻO nā kaʻina hana hana monolithic-i hoʻolālā ʻia i ka hopena-a-hope a puni kahi ʻano kaʻina hoʻokahi-hiki ʻole i ka wā e hālāwai ai kahi papahana i kahi peptide paʻakikī.. I ka hoʻohui ʻana i ka SPPS, ʻO nā ʻano hana hāʻule maʻamau e pili ana i nā hemahema hoʻohui hydrophobic i nā kaʻina kaulahao lōʻihi, ka hoʻohui ʻana ma-resin i manaʻo ʻole ʻia i ka wā lōʻihi synthetic cycles, a hāʻule hāʻule i ka pae deprotection ke pale ʻole ʻia nā kūlana hoʻoneʻe hui i kēia papa kaʻina kikoʻī.. Ke monolithic ke kaʻina hana, ʻO kēlā me kēia hemahema e pono ke kūkulu hou ʻia mai ka wā ʻōpala. Ke hana modular, hiki ke hoʻokaʻawale ʻia kēlā me kēia hemahema i kahi hana ʻāpana kikoʻī a hoʻoponopono ʻia me ka hoʻopilikia ʻole i nā mea ʻē aʻe.
Pehea e hoʻokō ai. Hoʻonohonoho ka papa hana peptide synthesis modular i ka hana ʻokoʻa, nā poloka hiki ke hoʻonohonoho hou ʻia: koho ala (SPSS, LPPS, ʻāpana ʻāpana-condensation), kemika hui (nā mea hoʻāla hoʻāla, manawa pōʻai, nā hoʻomalu mahana), ka hoomaemae ana (hoʻolālā gradient RP-HPLC hoʻomākaukau, nā pae hoʻohālike hoʻohui hakina), a me ka hooponopono ana (hoʻololi kūʻē, pōʻai lyophilization, ka hoʻoheheʻe ʻana). Hāʻawi kēlā me kēia poloka i nā mea hoʻokomo i wehewehe ʻia, nā mea hoʻopuka, a me ka ʻae ʻana ʻaʻole i hilinaʻi i nā kikoʻī o nā poloka pili.
No nā kaʻina i luna 30 nā amino acids a i ʻole nā pae hoʻololi he nui, ʻO Neuland 2026 Alakaʻi hoʻomohala CMC paipai ʻia i kahi ʻanuʻu ʻimi ala ala ma mua o ka hana ʻana i kekahi ala synthesis: e loiloi i ka SPPS me nā ʻāpana ʻāpana hybrid me ka hoʻohana ʻana i nā sub-sequences pōkole, me ka maʻemaʻe a me ka hua e like me ka hoʻoholo ʻana ma mua o ka hoʻohālikelike ʻana i kahi molekala kūleʻa mua.
ʻO kahi papa hana hoʻoholo koho ala kūpono:
|
Hiʻona kaʻina |
ʻO ke ala synthesis makemake |
ʻO ka pilikia nui e nānā |
|---|---|---|
|
≤20 AA, koena maʻamau |
SPSS (Fmoc) |
ʻO ka hōʻiliʻili ʻana |
|
21–35 AA, koena maʻamau |
SPPS me nā mana racemization |
Hoʻohui piha i kēlā me kēia pōʻai |
|
>35 AA a i ʻole nā mea paʻa disulfide lehulehu |
ʻO ka ʻāpana ʻāpana huila condensation |
ʻĀpana ʻāpana hale kūʻai pono |
|
He nui ka hydrophobic |
SPPS me pseudoproline dipeptides |
ʻO ka hui ʻana ma ka resin |
|
Nā kūlana i hoʻopaʻa ʻia i ka Isotope |
SPPS me nā koena isotopologue i pale ʻia |
ʻO Scrambling ma ke kaʻina hana |
Pehea ke ano o ka hemahema. ʻO kahi papahana e hoʻokuʻu i ka mākaʻikaʻi ala a hoʻopili i ka pōʻaiapuni SPPS like i kahi kaʻina hydrophobic 40-koena e like me kahi peptide maʻamau 15-koena e hana i kahi ʻike haumia i hoʻomalu ʻia e nā ʻoki ʻoki a me nā mea hoʻopau holoi.. Ua like ke ano o keia mau ano me ke ka'ina i ho'opa'a 'ia a hui pū ma lalo o nā kūlana gradient ma'amau. He pipiʻi ka hoʻomohala ʻana i ke ʻano hana hoʻihoʻi hou ma ia pae a hoʻopaneʻe i ka laina manawa i lalo i nā pule.
Haʻawina 2: Pono ka hoʻomohala ʻana o ke ʻano wikiwiki i ka ʻikepili Platform, ʻAʻole nā ʻano hoʻohālikelike o kēlā me kēia kaʻina
No ke aha ia mea. ʻO kekahi o nā paʻakikī no ka hana ʻana i ka lāʻau lapaʻau mRNA pilikino ʻo kēlā me kēia mea maʻi e koi ai i kāna iho hoʻokuʻu hoʻāʻo.. E like me ka ʻO nā lāʻau lapaʻau MDPI 2022 hōʻike hoʻomohala ma ka FRAME-001 lāʻau lapaʻau neoantigen palapala ʻia, ʻO kēlā me kēia ʻāpana peptide synthesized makemake i ka hoʻāʻo waena (helehelena, wahi % ka maemae, ʻike ʻia e UPLC-MS) a hoʻokuʻu hoʻāʻo (ka maemae, ʻike ʻike, endotoxin, sterility) ma mua o ka hoʻokumu ʻana i ka wai. Ke holo nei i ka pōʻaiapili hana maʻamau no kēlā me kēia 20 ʻAʻole hiki ke hoʻokō ʻia nā peptides i kēlā me kēia maʻi ma ka pae lapaʻau; ʻO ka hoʻonā ʻana, ʻo ia nā ala paepae e pili ana i nā kaʻina me ka ʻole o ka hōʻoia hou ʻana.
Hoʻoponopono ka loiloi like i ka ʻike ʻana i ka peptide a me nā papahana CMC me nā ʻano hoʻololi kiʻekiʻe. ʻEkolu mau waiwai o ke ʻano analytical platform: uhi ia i ka laula lehulehu i manaʻo ʻia a me ka laulā hydrophobicity o ka papa kaʻina, hoʻokaʻawale ia i nā papa hana o nā haumia pili kaʻina hana mai ka piko nui ma lalo o kahi kūlana gradient hoʻokahi, a hoʻopuka ia i kahi moʻolelo chromatographic hiki ke hana hou ʻia ma nā ʻāpana a me nā mea loiloi me ka ʻole o ka calibration kikoʻī..
Pehea e hoʻokō ai. Ka liʻiliʻi liʻiliʻi viable analytical pūʻolo no ka liʻiliʻi-puʻe, nā polokalamu hoʻololi kiʻekiʻe:
-
RP-HPLC a i ʻole UPLC hana maʻemaʻe: C18 kolamu ākea-pore (300 Å nui pore, 5 ʻāpana µm a i ʻole sub-2 µm no UPLC), gradient laina mai 5% i 60% acetonitrile i loko 0.1% TFA ma luna o 20-30 minuke, ʻIke UV ma 214 nm. ʻIke ʻia ma 214 Lawe ʻo nm i ka hoʻopaʻa ʻana o ka amide bond o nā iwi kuamoʻo peptide āpau a ʻo ia ka lōʻihi hawewe kuhikuhi no ka helu maʻemaʻe ʻāpana-pakeneka kūpono i nā kaʻina me nā koena ʻala..
-
ʻO ke ʻano ʻike LC-MS: Electrospray ionization (ESI), ʻano maikaʻi, ʻike ʻia ka hōʻike ʻana i ka monoisotopic a i ʻole ka awelika nuipaʻa kūʻē i ka waiwai theoretical, me ka hapa nui i ʻōlelo ʻia ma nā daltons a i ʻole ppm. Pono e hoʻopaʻa ʻia ke ʻano ionization a me ka calibration maʻamau i ka ʻikepili puʻupuʻu - ʻaʻole wale ka "mass match theoretical."
-
Kaʻina hoʻoili protocol: Ke lawelawe ʻia nā mea kūʻai aku a i ʻole nā lab hoʻāʻo i nā pae like ʻole o kahi papahana, aligning column chemistries, nā māka pae kelepona, a ʻo nā ʻāpana ʻike ma mua o ka hana ʻia ʻana o ka pūʻulu mua e pale aku i nā ʻokoʻa haumia ʻike ʻia mai ka ʻokoʻa o ke ʻano ma mua o ka hoʻololi ʻana o ka huahana.. ʻO ka nā protocols hoʻoili analytical harmonized i wehewehe ʻia i loko o nā papahana peptide CMC lehulehu e hōʻike mau ana i nā ʻano HPLC misaligned ma waena o kahi mea hana API a me kahi CRO bioanalytical e hana i nā holo kikoʻī hou e hoʻohui i nā pule i ka manawa me ka ʻole o ka hoʻoholo ʻana i nā nīnau maikaʻi maoli..
Pehea ke ano o ka hemahema. ʻIke ʻia ma 254 nm a i ole 280 nm—hoʻohana mau ʻia i loko o nā keʻena ʻoihana no ka nānā ʻana i ka UV maʻamau—e nele loa i nā mea ʻala ʻole. ʻO kahi pūʻulu peptide i hōʻike ʻia he ≥95% maʻemaʻe ma 280 hiki i ka nm ke hōʻike i kahi ʻike haumia ʻokoʻa ma 214 nm inā loaʻa iā ia nā huahana oxidation a i ʻole nā ʻāpana ʻoki ʻia me nā kaulahao ʻaoʻao ʻala. No kēlā me kēia peptide i hāʻawi ʻia ma ke ʻano he reagent mea hana ola a i ʻole ke kikowaena waena, ʻAʻole kēia he koho calibration - he ʻike a me ka maʻemaʻe āpau e pili ana i ka hana hou ʻana o ka hoʻokolohua..
ʻO ka mea a mākou e ʻike ai ma ka hana. I kā mākou papahana peptide pono'ī, ka 214 nm kue 280 ʻAʻole hiki ke hōʻike ʻia ka ʻokoʻa nm ma ke ʻano he helu nui hoʻokahi - hōʻike ʻia ma ke ʻano he kumu. Ke nānā hou mākou i kahi pūʻulu i maʻemaʻe ma lalo o a 280 ka nānā ʻana i ka nm, ka chromatogram ma 214 Hōʻike mau ʻo nm i nā ʻano haʻahaʻa haʻahaʻa ʻaʻole i hoʻopaʻa inoa ʻia nā lōʻihi hawewe ʻala wale nō: nā puʻupuʻu truncation mua, nā poʻohiwi oxidation late-eluting, a me nā ʻaoʻao kiʻekiʻe kiʻekiʻe i hoʻonui ʻia e hōʻailona ana i ka hoʻoneʻe hapa. He liʻiliʻi ka nui o ka ʻāpana i pili i kēia mau ʻano, akā, hoʻololi ko lākou hele ʻana i ke ʻano o kā mākou wehewehe ʻana i ka hailona-a, ʻoi aku ka mea nui, hoʻololi ia i ka hoʻoholo ʻae. ʻO ia ke kumu he maʻalahi kā mākou lula hana: inā ʻaʻohe koena ʻala o ke kaʻina, a i ʻole inā hoʻolālā ka mea kūʻai aku e hoʻohana i ka mea i loko o kahi haʻawina hoʻolālā-hana a i ʻole ke aʻo paʻa, mālama mākou 214 nm e like me ka lōʻihi hawewe hōʻike me ka nānā ʻole i ka a 280 hōʻike ʻo nm scan. ʻO ka haʻawina no kēlā me kēia mea e wehewehe ana i ka ʻikepili peptide ʻaʻole ia he "pololei" hoʻokahi nalu a he "hewa" ʻē aʻe - ʻo ka lōʻihi hawewe ʻike he koho ʻepekema e kūpono i ke kaʻina a me ka hoʻohana ʻana i lalo., ʻaʻole kahi paʻamau lab i hoʻoili ʻia mai kahi kaʻina hana pili ʻole.
Haʻawina 3: Pono ka ho'āʻo ʻike a me ka haumia i Orthogonal a pae
No ke aha ia mea. ʻO ka maʻamau maʻamau o ka analytical quality gap i ka hāʻawi ʻana i ka peptide liʻiliʻi e hoʻohui i ka maʻemaʻe me ka ʻike. Hoʻokumu ka RP-HPLC wahi-pakeneka o ka maʻemaʻe i ka hapa o ka hōʻailona i ʻike ʻia e pili ana i ka piko nui—ʻaʻole ia e hōʻoia ʻo ka piko nui ke kaʻina i manaʻo ʻia.. Hōʻoia ka mass spectrometry i ke kaumaha molekala o ka ion nui-ʻaʻole ia e kāpae i ka hui pū ʻana i nā haumia isobaric a i ʻole nā isomers sequence e kaʻana like i ka nuipa inoa like..
A 2023 ka nānā ʻana i nā kūlana kuhikuhi USP no ka maikaʻi o ka lāʻau peptide synthetic, paʻi ʻia ma ka Journal of Pharmaceutical and Biomedical Analysis, ua maopopo i keia hookaa ana: ʻike ʻike, ka maemae, maʻiʻo, a ʻo ka hoʻopili ʻana i ka haumia he mau pahuhopu analytical kaʻawale e koi ana i nā ʻano hana ʻokoʻa. ʻAʻole e māʻona kekahi i kekahi.
No nā polokalamu pilikino, pili kēia koi orthogonality ma ka pae hailona, ʻaʻole wale ma ka hōʻoia huahana. Lawe kēlā me kēia pūʻulu i kona mōʻaukala synthesis ponoʻī a no laila kona ʻike pilikino ponoʻī. ʻAʻole hiki ke hoʻohui ʻia i ke koena 14 ʻO kahi kaʻina 25-koena e hoʻopuka i kahi analog holoi ʻana e hiki ke kaʻana like i ka manawa paʻa me ka pahuhopu ma lalo o kahi gradient i hoʻopaʻa ʻia no ka peptide lōʻihi piha akā loaʻa kahi nui like ʻole - ʻike ʻole ʻia e ka ʻike UV wale nō..
Pehea e hoʻokō ai. ʻO kahi protocol hoʻāʻo pae i hoʻopaʻa ʻia i ka pōʻino puʻupuʻu:
|
Papa hoao |
I ka manawa e noi ai |
Pūʻolo analytical core |
|---|---|---|
|
Pākuʻi hoʻokuʻu wikiwiki |
ʻO ka hapa mua o kahi mea hou ʻO nā Peptides Synthetic kaʻina maʻamau |
RP-HPLC maemae (214 nm, me ka chromatogram) + ʻIkepili LC-MS (ʻōlelo ʻia ka hewa nui, ppm) |
|
Pono ka hailona maʻamau |
Hoʻonohonoho hou i kahi kaʻina i ʻike ʻia |
RP-HPLC maemae vs. chromatogram kuhikuhi paʻa + LC-MS hōʻoia ʻike |
|
Hōʻike hoʻonui |
Nā kaʻina paʻakikī: >30 AA, mau hoʻololi, ala hou |
Nā kūlana RP-HPLC Orthogonal + LC-MS/MS ʻāpana ʻāpana + AAA no ka haku mele |
|
Hoʻohana hana a lapaʻau paha |
Ka hoʻāʻo ma ke kelepona, haʻawina holoholona, huahana lāʻau i hoʻokumu ʻia |
ʻO ka pae piha ma luna + endotoxin (LAL ala), kaumaha olaola, koena solvent, mea kūʻē |
No ka hoʻopili ʻana i ka haumia, ʻO nā papa hana haumia i loaʻa mai i ka SPPS e nānā: nā kaʻina i ʻoki ʻia (ka holoi ʻana i hoʻokahi a ʻoi aku paha koena, e kū ana ma ka kuhikuhi C-terminal); huahana hoʻohāhā (Met, Trp, a me Cys ma ke ano he mau kahua kumu, ʻoi aku ka lōʻihi ma hope o ka lawelawe ʻana); ʻano hoʻopau hoʻopau ʻole (ʻO ka hoʻomau Pbf ma Arg ka mea maʻamau ma lalo o nā kūlana cleavage pōkole); a me ka hoʻokomo ʻana i nā analogs mai ka racemization i nā koena i hoʻāla ʻia i ka wā o ka hui ʻana. Hiki iā LC-MS/MS ke hoʻokaʻawale i ka hapa nui o kēia mau papa ma ke ʻano ʻāpana, akā ʻo ka mea i koi mua ʻia he ala RP-HPLC baseline e hoʻokaʻawale iā lākou mai ka piko nui ma mua o ka hoʻohui ʻana iā lākou i kahi ʻāpana ākea hoʻokahi..
⚠️ Hoʻokaʻawale koʻikoʻi: "ʻO ka maʻemaʻe ≥95% e HPLC" a me ka "ʻike i hoʻopaʻa ʻia e MS" ʻelua mau ʻīpuka maikaʻi ʻokoʻa - ʻaʻole e māʻona kekahi i kekahi.. No kekahi peptide lot e komo ana i ka biological assay a i hāʻawi ʻia ma ke ʻano he mea hana, koi ʻia nā mea ʻelua. Hōʻike ʻia nā ʻōkuhi no ka mea e pono ai ka moʻolelo palapala analytical piha i ka hana ka hoʻomaikaʻi ʻana i ka palapala maikaʻi i ka mākeke peptide noiʻi, kahi i ʻike ʻia ai ka ʻāpana hoʻopihapiha hoʻopaʻa ʻana like me kahi manaʻo maikaʻi ʻōnaehana.
ʻO ka ʻO ka palapala protocol hoʻāʻo ʻike ʻike AxonVerified (2026) haʻi pololei i ka loina hana: Hōʻike kēia ʻano hana ʻelua i ka maʻamau i hoʻohana ʻia i ka hoʻāʻo ʻana i ka lāʻau lapaʻau i hoʻopaʻa ʻia - ʻo ka helu maʻemaʻe e hoʻokumu i ka nui o ka hāpana ʻo ka pūhui pahuhopu., ʻoiai ʻo ka hōʻoia ʻike e hoʻokumu i ke ʻano o ia hui. E pili ana
Haʻawina 4: Pono ka Palapala Hoʻopaʻa liʻiliʻi i kahi kumu hoʻohālike i kūkulu ʻia
No ke aha ia mea. Nā ʻano hoʻopaʻa moʻolelo puʻupuʻu maʻamau i hoʻolālā ʻia no ka nui, ʻAʻole hoʻokō ka hana peptide hoʻokahi i ka wikiwiki o ka hana a i ʻole ka hoʻololi ʻana o nā papahana kiʻekiʻe.. He loiloi i paʻi ʻia e PolyPeptide ma neoantigen peptide hana hana hai pololei: ʻAʻole ʻae nā moʻolelo batch maʻamau i hoʻohana ʻia i ka hana peptide kuʻuna i ka maʻalahi a me ka wikiwiki e pono ai no ka hana peptide neoantigen., a pono e hoʻomohala a hoʻohana ʻia kahi palapala hōʻike pūʻulu GMP maʻalahi akā piha. Hana ʻia ʻo Peptide
Pili ka hopena like i kēlā me kēia puʻupuʻu liʻiliʻi, ʻO ka polokalamu peptide kiʻekiʻe e holo ana ma lalo o nā manawa i hoʻopaʻa ʻia - inā he wai peptide neoantigen no kahi keʻena immunology hoʻonaʻauao., he panel maʻamau i loko i kapa ʻia ka isotope maʻamau no kahi hōʻike PK/PD, a i ʻole he pūʻulu o nā analogs i hoʻololi ʻia e loiloi ʻia i nā haʻawina SAR like.
Pehea e hoʻokō ai. ʻO kahi pūʻolo palapala kūpono no nā papahana peptide liʻiliʻi he ʻeono mau mea traceability:
-
Hoʻopaʻa moʻolelo: ʻO ke kaʻina amino acid piha, nā kūlana hoʻololi, hoʻolālā hui pale, a me ka hoʻonohonoho ala (SPSS, huikau, etc.). Pono e hoʻokomo i kahi hōʻailona maʻemaʻe maʻemaʻe ma mua o ka hoʻokō ʻana o ka hui i ka hoʻomaʻemaʻe, no laila ua hōʻailona ʻia nā ʻāpana palena ma mua o ke koi ʻia.
-
mooolelo analytical lot-specific: RP-HPLC chromatogram makaʻala (paʻa ʻole, me ka hōʻike hoʻohui ma 214 nm), LC-MS piha kikoo (nuipa theoretical, nuipa i nānā ʻia, ʻano hoʻokaʻawale, mea kani, maʻamau calibration), a ma kahi e pili ai, AAA a i ʻole nā hōʻoia orthogonal ʻē aʻe. Pono e mālama ʻia nā faila ʻikepili maka—ʻaʻole wale ka papa hōʻuluʻulu manaʻo.
-
Palapala ʻike kaulahao: No nā papahana kahi i loaʻa mai ai ke kaʻina peptide mai kahi kumu olaola kikoʻī (biopsy ma'i, kelepona ʻokoʻa, ʻO ka hana genotype HLA), Pono ke ala palapala e hoʻopili i ka mea ʻike kumu i ka kikoʻī synthesis i ka helu hailona i ka moʻolelo hoʻokuʻu. ʻO kēia ka peptide-ʻaoʻao like o ke kaulahao-o-ʻike pono i nā papahana hana mRNA a hiki ke loiloi ʻia ma lalo o nā loina ʻōnaehana maikaʻi o ICH Q10..
-
Hoʻokuʻu papa kuhikuhi: Nā pae hoʻohālike ʻae ʻia no kēlā me kēia ʻano i hoʻāʻo ʻia, ʻōlelo ʻia ma ka helu. “Maemae: ≥95.0% e RP-HPLC wahi ma 214 nm" he kiko'ī. ʻAʻole "maʻemaʻe kiʻekiʻe".. ʻO ka EMA Alakaʻi no ka hoʻomohala ʻana a me ka hana ʻana o nā Peptides Synthetic pono e hoʻonoho ʻia nā palena maʻemaʻe a me ka haumia me nā ʻano analytical wehewehe a me nā paepae kūpono. Pono e mālama ʻia kēlā kūlana ma ke ʻano he papahele, aole he kaupaku, ʻoiai ma ka hana pre-IND.
-
Kuhikuhi hailona comparability heleuma: ʻOiai ma nā papahana noiʻi, ʻo ka mālama ʻana i hoʻokahi pūʻulu i hōʻike ʻia i kēlā me kēia kaʻina e hiki ai ke loiloi ʻia nā hailona e hiki mai ana i kahi papa kuhikuhi.. He hana haʻahaʻa haʻahaʻa kēia me ka waiwai nui o lalo i ka wā e kū mai ai nā nīnau ikaika o ke ʻano a i ʻole ke hoʻololi ʻana o ka mea kūʻai aku e pono ai ka hōʻike hoʻohālikelike.. A peptide IND CMC papa inoa i hoʻomohala ʻia no nā papahana IND-stage e hāʻawi i kahi laʻana kūpono no ka hoʻonui ʻana i nā koi palapala i ka wā e holomua ai ka pae hoʻomohala.
-
ʻO ka hoʻopaʻa ʻana a me ka piʻi ʻana: He kahua e ʻike ana i ka hoʻokaʻawale ʻana o ka synthesis — ʻike ʻia ka hemahema o ka hui ʻana e ka ninhydrin a i ʻole ka nānā ʻana o UV., hoʻololi resin i waena o ka synthesis, hoʻololi gradient i ka wā hoʻomaʻemaʻe—a me ka pane i lawe ʻia. No nā polokalamu e hoʻohana ana i nā CDMO waho a i ʻole nā mea kūʻai aku he nui, ʻO kēia moʻolelo ke ʻano e ʻike ʻia ai ka neʻe ʻana o ke kaʻina hana ma mua o ka lilo ʻana i mea maikaʻi ʻole.
Pehea ke ano o ka hemahema. ʻO kahi papahana e hāʻawi ana i nā peptide lot me ka ʻikepili CoA i kaupalena ʻia i ka waiwai maʻemaʻe HPLC hoʻokahi a me ka hōʻoia nui o ka inoa ʻaʻohe mea hana no ka ʻike ʻana i ka neʻe ʻana o ka lot-to-lot i loko o ka ʻike haumia., ʻaʻohe kumu no nā koi hoʻohālikelike, a ʻaʻohe ʻōnaehana maikaʻi e pale ʻia inā hoʻi ka hemahema o ka assay i ka mea peptide. Ma nā papahana hoʻonaʻauao, ʻike pinepine ʻia kēia ma ke ʻano he ʻikepili pane-pane hiki ʻole ke hoʻopili ʻia i ka ʻokoʻa olaola. I nā papahana biopharma, ʻike ʻia ma nā ʻano ʻawaʻawa a i ʻole nā leka IND me ka ʻoihana.
Pehea ke ano o ka hemahema. ʻO kahi papahana e hāʻawi ana i nā peptide lot me ka ʻikepili CoA i kaupalena ʻia i ka waiwai maʻemaʻe HPLC hoʻokahi a me ka hōʻoia nui o ka inoa ʻaʻohe mea hana no ka ʻike ʻana i ka neʻe ʻana o ka lot-to-lot i loko o ka ʻike haumia., ʻaʻohe kumu no nā koi hoʻohālikelike, a ʻaʻohe ʻōnaehana maikaʻi e pale ʻia inā hoʻi ka hemahema o ka assay i ka mea peptide. Ma nā papahana hoʻonaʻauao, ʻike pinepine ʻia kēia ma ke ʻano he ʻikepili pane-pane hiki ʻole ke hoʻopili ʻia i ka ʻokoʻa olaola. I nā papahana biopharma, ʻike ʻia ma nā ʻano ʻawaʻawa a i ʻole nā leka IND me ka ʻoihana.
ʻO kā mākou mea kūʻai e haʻi mai iā mākou. ʻO nā nīnau a mākou e lohe pinepine ai mai nā pūʻulu noiʻi ʻaʻole loa e pili ana i ka synthesis - pili lākou i nā palapala. ʻElua hoʻi hou me ke ʻano kūlike. ʻO ka mua he mana o "ka palapala hōʻoia 98% maemae, akā ʻo ia ka peptide kūpono?”—ka ʻike, hiki mai ma hope o ka hopena ho'ā'o pohihihi, ʻaʻole i hoʻokumu ʻia kahi kiʻi maʻemaʻe wale nō. ʻO ka lua he nīnau hoʻohālikelike: "Ua hoʻonohonoho hou mākou i ke kaʻina like ʻeono mahina ma hope a loaʻa kahi hopena ʻē aʻe - ua loli ka huahana, a i ʻole ka hoʻāʻo ʻana?” Ma na hihia elua, like ka pono kumu: he ala palapala e hoʻohui i ke kaʻina, ka ʻikepili maka, nā pae hoʻokuʻu, a me kekahi kuhi hewa i loaa ma ke ala. No ka mea, ke kūkulu nei mākou i kahi moʻolelo kiʻekiʻe loa no kēlā me kēia kaʻina hana - me nā faila RP-HPLC a me LC-MS maka., ʻaʻole wale ka laina hōʻuluʻulu—hiki ke pane ʻia kēia mau nīnau mai ka waihona pūʻulu ma mua o ka hoʻohui hou ʻana a me ka hoʻāʻo hou ʻana.. ʻO ia ka waiwai kūpono o nā palapala kūpono no ka hana: hoʻololi ia i ka hopohopo o ka mea kūʻai aku i mea maʻamau, pane loiloi.
Hoʻohui i nā haʻawina mRNA i ka hoʻolālā holo kaʻina hana peptide: He Hōʻuluʻulu Manaʻo
Hōʻike ka papa ma lalo i nā haʻawina hana ʻehā mai nā papahana kano mRNA pilikino i kā lākou hana like i ka peptide analytics a me ka hoʻomaʻamaʻa CMC..
|
ka pilikia hana mRNA |
ʻO ka hoʻokūkū peptide parallel |
Hana hoʻomalu |
|---|---|---|
|
ʻAʻole hiki i nā pūʻulu n-of-1 ke hahai i kahi kaʻina monolithic |
Pono ka hoʻololi ʻana o ke kaʻina kiʻekiʻe i nā ala synthesis hiki ke hoʻonohonoho hou ʻia |
Papahana modular: mākaʻikaʻi ala me nā mea hoʻoholo hoʻoholo i wehewehe ʻia, ʻāpana-hana-level ʻae ʻae |
|
Pono kēlā me kēia ʻāpana maʻi i kāna pōʻai hoʻāʻo ponoʻī |
Loaʻa i kēlā me kēia ʻano kaʻina kaʻina i kahi ʻano ʻokoʻa pilikia o ka haumia |
Nā ʻano analytical platform (RP-HPLC maʻamau + LC-MS) e uhi ana i ka papa kaʻina piha |
|
ʻO ka maʻemaʻe a me ka ʻike he mau puka hoʻokuʻu kaʻawale |
Maʻemaʻe HPLC ≠ ʻike MS; koi ʻia nā mea ʻelua i ka hailona |
ʻO ka hoʻāʻo Orthogonal: RP-HPLC ma 214 nm + ESI-MS me ka hapa nui i hōʻike ʻia |
|
Pono e hoʻopaʻa ʻia ke kaulahao mai ka biopsy a hiki i ka hoʻokuʻu ʻana |
Pono ka ʻike kumu-a-lot no nā kaʻina i loaʻa mai i ka biologically |
Nā moʻolelo pūʻulu i kūkulu ʻia me ʻeono mau mea traceability me ka mālama ʻana i ka ʻikepili maka |
|
Paʻa loa nā moʻolelo pūʻulu GMP maʻamau no nā kaʻina manawa pilikino |
ʻAʻole i hoʻolālā ʻia nā moʻolelo synthesis maʻamau no ka pōkole, nā polokalamu hoʻololi kiʻekiʻe |
Nā palapala palapala maʻalahi akā hoʻopiha piha, pae-kūpono |
ʻAʻole kēia hoʻohālikelike he hoʻopaʻapaʻa no ka hoʻohana ʻana i nā mana GMP clinical i nā peptides noiʻi mua. He paio no ka hoohana ana i ka hale hoʻolālā o ia mau mana—modular production thinking, ʻānai ʻana i ka orthogonal, nā palapala i hoʻopaʻa ʻia—ma ke ʻano o ke koʻikoʻi kūpono i ka papahana. Hoʻokuʻu pinepine nā papahana noiʻi i kēia mau mana ʻaʻole no ka mea ʻaʻole pili ka loina kumu, akā, no ka mea, ʻaʻohe mea nāna i unuhi i ka framework i nā mea paʻa pono no ka pōʻaiapili non-GMP.
He aha kāu e hana ai inā ʻoi aku kāu polokalamu ma mua o ʻelima mau kaʻina
Inā hoʻopuka kāu polokalamu i kēia manawa i nā pūʻulu ma waena o ʻelima mau kaʻina like ʻole, a i ʻole ka holomua ʻana i nā mea e pili ana i nā hoʻokolohua hana a me nā noiʻi holoholona, ʻekolu mau manaʻo hoʻoholo kaʻina hana e hoʻoholo i ka hapa nui o ka pilikia o ka maikaʻi o lalo:
E kuhikuhi i ke ala ma mua o ka hana ʻana: Ke hoʻohana nei kāu hui a i ʻole CDMO i kahi protocol scouting i kūkulu ʻia me nā mea hoʻoholo hoʻoholo, a i ʻole ke koho ʻana i ke ala e hoʻoholo ʻia e ka mea kūʻai aku a me ke ʻano hoʻohālikelike i nā molekala mua?
Hoʻopiha hoʻopaʻa ʻana: Loaʻa i kēlā me kēia hailona i hoʻokuʻu ʻia ka ʻikepili maʻemaʻe RP-HPLC i ʻike ʻia ma 214 nm (me ka chromatogram maka), Hōʻike ʻia ka ʻikepili ʻike ESI-MS me ka hapa nui, a me ka paʻa ʻana o nā faila mea hana maka—a i ʻole he papa hōʻuluʻulu wale nō?
Hiki ke hoʻopaʻa palapala: Hiki ke ʻike ʻia kahi anomaly maikaʻi ma kahi hoʻāʻo i ka moʻolelo puʻupuʻu, ka log deviation synthesis, a me ka ʻikepili ʻikepili maka mua ma lalo 30 minuke?
ʻO ka MOL Changes Hoʻopuka ka platform peptide synthesis maʻamau i nā pūʻolo palapala pae nui e uhi ana i nā chromatograms RP-HPLC, kiʻekiʻe ESI-MS spectra, a me ka hōʻoia hōʻoia ʻike hewa nui no kēlā me kēia kaʻina hana - e hoʻohana ana i ka hoʻokolohua hoʻāʻo orthogonal like i wehewehe ʻia ma kēia ʻatikala i nā kaʻina papa inoa maʻamau a me nā hoʻololi maʻamau paʻakikī.. Hiki i nā hui ke kūkulu a hōʻailona paha i kā lākou peptide workflows e kū'ē i kēia anga ke noi i kahi loiloi kūpono ʻenehana e uhi ana i ke koho ala synthesis., hoʻolālā hoʻomalu haumia, a me ka hoʻolālā papapalapala palapala no nā papahana hoʻololi kiʻekiʻe.

